




VOLTRON THERAPEUTICS, INC.

Investor Presentation • July 2021



DISCLAIMER AND SAFE HARBOR

This document does not constitute an offering document. Potential investors or shareholders should not rely on the information contained in this document before making an investment decision. This presentation is being provided for the sole purpose of providing the recipients with background information about Voltron's business. This presentation, including the information contained in this disclaimer, does not constitute an offer, invitation or recommendation to subscribe for or purchase any security and neither the presentation, disclaimer nor anything contained in them forms the basis of any contract or commitment.

DISCLAIMER AND SAFE HARBOR

Safe Harbor Statement

This presentation contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of revenues, future national or regional economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this presentation.

VOLTRON CORPORATE OVERVIEW

VOLTRON is a pre-clinical biotech company focused on bringing our Self-Assembling Vaccines (SAV) to patients with certain cancers or infectious diseases.

Infectious pathogens, such as COVID-19.

- Positive results in generating immunity against COVID-19 in recent animal testing recently reported

Specific cancers, particularly those related to human papilloma virus (HPV)

- We believe that our vaccines could be synergistic with existing therapies and improve patient outcomes by engaging the immune system to identify and attack certain cancers.

Initial proof of concept:

- Lassa Fever and Q Fever, emerging infectious diseases, via MGH research
- This was done, in part, with the support of the Department of Defense (DoD). These same principles are being applied to developing a vaccine against the pandemic coronavirus, known as COVID-19

Oncology development underway, with animal testing to follow

Manufacturing scale-up in process; GMP material for first-in-man studies to be ready in 1Q21

Strong leadership team in place

Strong intellectual property surrounding composition of matter. Incorporating HSP70 more broadly activates the immune system in contrast to prior vaccine efforts which used classic adjuvants like alum, etc. The vaccine is 90% HSP70 and Avidin. Biotinilated Neoantigens are then incorporated to customize the vaccine.

VOLTRON THERAPEUTICS AT-A-GLANCE

COMPANY BACKGROUND:

- Voltron Therapeutics, Inc. was formed in 2017 as a Delaware Corporation for the purpose of licensing the VaxCelerate self-assembling vaccine platform from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
- The Company's principal place of business is 12 E. 49th St., 11th Floor, New York, NY 10017

Funding:

- Mass General Hospital & the VIC's SAV research in oncology was initially funded by Majella Partners.
- VIC's initial work on SAV for infectious diseases has been funded to date by grants from the US DoD.
- \$3.6 million convertible Series A raised in 2020
- The company also received funding under an agreement with Hoth Therapeutics, Inc (NASDAQ: HOTH)

VOLTRON THERAPEUTICS RECENT PROGRESS

RECENT DEVELOPMENTS: VACCINE DEVELOPMENT & CORPORATE PROGRESS

1

Advanced animal work with positive data in our latest animal model for HaloVax

- Generated T-cell response in mice
- Important indicator for future efficacy studies

2

Added an important members to our Board of Directors –

Tony Zook

- Seasoned pharma/biotech CEO and Board member
- Served as CEO of Astra Zeneca NA

Paul Korner, MD

- Experienced biotech CMO
- Served as CMO of Sarepta Therapeutics, (SRPT), et. al.

3

Progressed manufacturing scale-up of mtbHSP70

- Will be used in both Oncology & ID applications

THE VAXCELERATE PLATFORM



Vaccine technology developed by MGH Vaccine & Immunotherapy Center at Harvard University to:

- Enable rapid generation and testing of vaccines for emerging infectious diseases.
- Use vaccine platform with flexibility for targeting a wide range of pathogens and consistency to facilitate regulatory review.
- Practice virtual collaboration with best-in-class academic and industry partners anywhere in the world.
- Position successful outputs for efficient translation to industry for further development.

Has demonstrated ability to generate and test de novo vaccine in 120 days.

- VIC execution of DARPA-funded “live fire” exercise for Lassa fever vaccine.

Vaccine technology has been licensed from MGH by Voltron Therapeutics.

VAXCELERATE SELF-ASSEMBLING VACCINE DESIGN

IMMUNE CELL-ACTIVATING COMPONENT


- Can be produced in advance and stockpiled
- Activates cellular immunity
- Highly stable fusion protein, with avidin integrated into the molecule

PATHOGEN-TARGETING COMPONENT

- Peptides based on in silico identification of immunogenic pathogen elements; biotin is integrated into the molecule
- Potential for rapid manufacture in “on demand” fashion for specific targets



Constructs
self-assemble
in solution



**SAME
CONFIGURATION FOR
EVERY VACCINE**

**HIGHLY
STABLE
VACCINE**

**DOES NOT INCLUDE
ADDITIONAL ADJUVANTS OR
COMPLEX FORMULATION**

HALOVAX OVERVIEW: COVID-19 VACCINE

- Play video from www.voltrontx.com

SIGNIFICANT UNMET MEDICAL NEED

INFECTIOUS DISEASES GLOBALLY

- COVID-19 has had massive global impact; variants are likely to be seen
- Future emerging infectious diseases likely



CANCER IMMUNOTHERAPY

Cervical Global Cases/Year

570,000

Current Treatments include Surgery, Radiation, Chemotherapy, Targeted Therapy, and PD-1

Head and Neck Global Cases/Year

550,000

Current Treatments include Surgery, Radiation, Chemotherapy, PD-1

Anal Global Cases/Year

30,000

Current Treatments include Surgery, Radiation, Chemotherapy

VOLTRON PIPELINE

Pre-Clinical

COVID-19

Pre-Clinical

CERVICAL CANCER

Pre-Clinical

HEAD & NECK CANCER

Pre-Clinical

ANAL CANCER

OPTIONS FOR ONCOLOGY TARGETING WITH THE VARIABLE PORTION



**CERVICAL
CANCER**



**HEAD AND
NECK CANCER**



**ANAL
CANCER**

ONCOLOGY MARKET SIZES & REVENUE POTENTIAL

	CERVICAL	HEAD AND NECK	ANAL
GLOBAL CASES/YR.	570,000	550,000	30,000
GLOBAL DEATHS/YR.	300,000	300,000	
US CASES/YR.	13,300	64,000	8,600
US DEATHS/YR.	4,200	14,000	1,200
SURVIVAL @ 5 YRS	Approx. 65%	Approx. 45%	Approx. 65%
CURRENT TREATMENTS	Surgery, Radiation, Chemotherapy, Targeted Therapy, PD-1	Surgery, Radiation, Chemotherapy, PD-1	Surgery, Radiation, Chemotherapy
MARKET POTENTIAL	~\$7 Billion	~1.5 Billion	~700 Million



VAXCELERATE PLATFORM PRECLINICAL TESTING RESULTS

Rapid Vaccine Generation and Testing



SAV CLINICAL EXPERIENCE – LASSA FEVER

VaxCelerate: Rapid development of a self-assembling vaccine for Lassa fever.

- Data published in the Dec. 1, 2014 issue of Human Vaccines and Immunotherapeutics demonstrated a self-mediated and augmented immune response.
- The concept has been validated in the infectious disease setting (Lassa fever) lead by the VIC team.

**SINCE THIS TIME, THE FDA HAS
BECOME COMFORTABLE WITH HSP70
THROUGH HUMAN EXPERIENCE AND
A PLETHORA OF SCIENTIFIC
RESEARCH/PAPERS.**



VOLTRON COVID-19 VACCINE PROGRAM: HALOVAX™

DESIGNED from the start to be adaptable to emerging virus targets such as COVID-19.

ABILITY to get into two animal models within 6 months with a retargeted vaccine.

WHY WE DIFFER

1

Designed for safety first, to avoid known vaccine adverse effects, such as excessive local response or inappropriate immune response that can make the disease worse

2

Risk of responses that can make disease worse in other approaches, which do not take into account the biology and immunology of coronavirus infection

3

Other approaches use existing vaccine platforms designed for other pathogens, and then try to adapt to COVID-19.

4

Primary focus on T-cell activation, vs B-cell generated antibodies, as seen with Operation Warp Speed vaccines

- Important alternative as virology evolves

HALOVAX PROOF OF CONCEPT: STUDY '087



The study met the primary endpoint of significant IFN γ production by T-cells isolated from the lymph nodes of vaccinated mice and exposed to the antigen in vitro

- IFN γ production is an indicator of T cell antiviral activity.




SAV induced IFN γ responses in both CD4 $^{+}$ and CD8 $^{+}$ T cells, indicative of a broad based antiviral activity.

Significant increases were also seen in T cells expressing the activation marker CD154 and both CD154 and IFN γ .

- CD154 is expressed by T cells that are engaged and actively responding to antigen.

No adverse effects of vaccination were noted, although the study was not designed to address safety and toxicity.

PROOF OF CONCEPT: STUDY '087



HALOVAX™ DEVELOPMENT



Designed and produce a Self-Assembling Vaccine (SAV) against COVID-19

- Two vaccine designs produced in sufficient quantity and quality for use in preclinical in vivo tests of immunogenicity and safety.

In vivo assessment of SAV-CoV vaccine response in 2 mouse models

- Proof-of-concept of vaccine immunogenicity in an animal model being used for FDA review.

In vivo assessment of SAV-CoV vaccine response and protection in Syrian Hamster model at Colorado State University currently ongoing

- Deliverable: Proof-of-concept of vaccine immunogenicity and protection

MANUFACTURING PROGRESS



Dr. Zachary Shriver has joined the team

to provide expertise in protein design, development and manufacturing; globally recognized expert in protein manufacturing

SCALE UP FOR PRODUCTION OF HSP70 IS PROCEEDING,
and is now on a path to GMP production by early 2021

PEPTIDE PRODUCTION progressing well and advancing
to GMP level

BACK-UP SITES identified



INTELLECTUAL PROPERTY:

Patent 0129484:

- Published in June of 2011- the SAV issued the patent covering the vaccine's composition of matter.
- In essence the patent covers the composition of a rapid, self-assembling vaccine designed to bind to multiple sites on tumors.
- Prior to this patent, no one had ever genetically assembled a fusion protein out of HSP70 and avidin.
- Opportunities exist beyond the initial patent as the team has recently reduced the number of binding sites required from 4 to 1- this could lead to more specificity.

A number of further IP disclosures and provisional patents are currently in the pipeline and planned

VOLTRON TEAM

ORGANIZATION	KEY LEADERSHIP AND ADVISORS	
VOLTRON THERAPEUTICS	Anthony Zook; Executive Chairman	Fmr. CEO, AstraZeneca NA
	Pat Gallagher; CEO, Director	Management & Finance
	Matthew Duffy; President, Director	Management & Finance
	Paul Korner, MD; Director	Clinical Development
	Zachary Shriver, PhD; CSO, Visterra Inc.	Manufacturing & protein design
VIC AT MGH	Mark Poznansky, MD, PhD; Director, VIC	Infectious disease immunology, translational research
	Michael Callahan, MD, DTM&H (UK), MSPH; Director, Translational Research, VIC	Emerging infectious diseases, biological product development
	Jeff Gelfand, MD; Senior Scientist, VIC	Infectious diseases, SAV technology inventor

VOLTRON LEADERSHIP TEAM

Patrick Gallagher, CFA – Chief Executive Officer

- Pat has 20 years of healthcare experience on Wall Street including alternative investments, research and marketing in both the public and private markets. He co-founded Black Diamond Research, LLC (“BDR”), an independent sell-side research firm specializing in healthcare investing, financing and operations, serving the institutional investing community at large.
- Patrick served as VP of Business Development and Investor Relations as well as a strategic consultant for Kinex Pharmaceuticals, a biotechnology firm focused on next-generation therapies in oncology and immunology (now traded on NASDAQ: ATNX). He also has served as an advisor to CHD Biosciences, a novel antimicrobial company. Mr. Gallagher serves on the board of directors of BioSig Technologies, Inc., NASDAQ listed a medical device company that is developing a proprietary technology platform in the electrophysiology space, Cingulate Therapeutics a therapeutics company with a novel drug delivery platform, and Evermore Global a global special situations money manager.
- Mr. Gallagher is also a Managing Partner at Laidlaw Venture Partners dba Laidlaw & Company (UK) Ltd. and is part of the Investment Banking Healthcare Team.

Matthew D. Eitner– Director

- Matthew Eitner serves as Chief Executive Officer at Laidlaw & Company (UK) Ltd. He joined the firm in 2010 and was named CEO in April 2011. Prior to Laidlaw, Mr. Eitner served as Managing Director of the private client group at Aegis Capital Corp., a private investment firm. Before Aegis Capital, Mr. Eitner was a Vice President at Casimir Capital, a boutique investment bank. Mr. Eitner’s experience includes his role as an equities trader at NDB Capital Markets, now Deutsche Bank, and as an Associate at International Strategy & Investment.
- Outside of the Firm, Mr. Eitner is involved in a number of charitable organizations, including Covenant House and Good Counsel Homes. Mr. Eitner is also a founding member of the Board of Trustees of Don Bosco Preparatory High School in Ramsey, NJ. Don Bosco Prep is a private, Catholic institution, administered by the Salesians of St. John Bosco.
- Matt Eitner is also a founding member of the Bergen County, New Jersey Chapter of Legatus, the world’s only membership organization for Catholic senior-level, legal, and medical executives and CEOs and their spouses.

VOLTRON LEADERSHIP TEAM

Anthony Zook – Executive Chairman

- Mr. Zook has served as our Executive Chairman and a member of the Board since December 2020. Mr. Zook was executive vice president of global commercial operations of AstraZeneca Plc from 2010 until 2012. He also served as president and chief executive officer of the North American division of AstraZeneca Plc from 2006 until 2009, and president of Medimmune, the company's wholly-owned biologics division from 2009 until 2010. Mr. Zook has served as a director of BioSig Technologies, Inc (Nasdaq: BSGM) since July 2020, and had previously served as a member of the Board of Directors of AltheRx from 2013-2014, InHibikase in 2014, Rib-X Pharmaceuticals in 2009, the National Pharmaceutical Council from 2007-2009, PhRMA from 2011-2012, the Pennsylvania Division of the American Cancer Society from 2005-2007 and his alma mater, Frostburg State University from 2016-2018 and re-joined in 2021, where he earned a B.S. degree. Mr. Zook also earned an A.A. degree in chemical engineering from Pennsylvania State University. Mr. Zook brings extensive commercialization experience and expertise in executive leadership, making him a valuable resource on the Board.

Paul Korner, MD, MBA, Director

- Paul Korner is physician executive with over 21 years of pharmaceutical/biotech industry experience, serving in senior R & D leadership position for Ferring Pharmaceuticals, Ardelyx Inc., Sarepta Therapeutics and Axovant Gene Therapies. He is currently the Chief Medical Officer of Agile Therapeutics, Inc. He has been responsible for multiple INDs/CTAs and more than 50 clinical trials (phase 1-4), leading to marketing authorization/approvals of 10 products including VYONDYS 53[®] (golodirsen) and several others. While serving as SVP Clinical & Medical Affairs at Axovant Gene Therapies, he advanced two gene therapy programs into IND and BLA enabling clinical trials for GM1 and GM2 gangliosidosis. He has been part of the LVP team for more than 3 years, providing strategic and operational scientific/clinical guidance to portfolio companies.
- Dr. Korner has experience across novel pathways including gene therapy, vaccines, small molecules, peptides, and biologics across all development phases and multiple therapeutic areas including rare disease, CNS, women's health, gastroenterology, nephrology, musculoskeletal/inflammation/orthopedics, and urology. Over the course of his career, he has authored fifty-one peer-reviewed publications across multiple disease states.
- Dr. Korner is a board-certified obstetrician and gynecologist who was in private practice in Glencoe Illinois and Riverdale Georgia prior to joining industry in 1998. He received his B.S. in Biology from the University of Illinois (Champaign/Urbana), M.D. from Loyola University, Stritch School of Medicine in Maywood Illinois. He also holds an M.B.A. from the Michael J. Coles College of Business at Kennesaw State University in Georgia.

VOLTRON LEADERSHIP TEAM

James P. Ahern – Director

- Jim brings over 15 years' experience to the Voltron team. His experience is directly relevant in capital formation, venture capital, investment banking and equity capital markets.
- Jim has spearheaded relationships with innovation laboratories at universities that has allowed for the incubation of multiple companies in the LVP Portfolio. He has also worked with multiple entrepreneurs as a funding and advisory partner to move therapeutics, medical technologies, and other assets forward.
- Jim has acted as a partner to a multitude of successful companies in the private setting, raising capital for emerging growth companies, assisting in expanding their networks, and ultimately providing a public pathway. In Jim's capital market experience, at Laidlaw he is credited with establishing a highly recognized quality fundamental health care brand. With a devotion to brand cognizance, Laidlaw Capital Markets is today recognized as a fundamental health care investment bank providing targeted outreach to relevant health care centric investors.
- As Head of Capital Markets at Laidlaw, Jim has led or been played an integral role in providing its clients with over \$6 billion in capital. Laidlaw is proud to have acted as sole placement agent on transactions of up to 100 million in transactional value, and alongside some of the highest quality health care centric banks on transactions above and beyond.
- Jim currently serves on the board of directors of Algorithm Sciences, Voltron Therapeutics, and PD Theranostics. In addition, proudly serves on the board of overseers of the Massachusetts Bay Big Brothers Big Sisters Foundation. Jim is Vice Chair of the annual BBBS golf outing, an event which brings in approximately 1 million dollars annually for the foundation. He's also a proud supporter of his alma mater, The Northfield Mount Hermon School, where is serves as Chairmen of the Basketball Academic Center of Excellence.

Matthew Duffy – President, Director

- Matt has served as Chief Executive Officer & board member of Algorithm Sciences, Inc. since September 2010, and has more than thirty years' experience in the healthcare arena, as both a healthcare and Wall Street executive.
- Mr. Duffy has extensive development-to-market experience, beginning at Pfizer, Inc., in 1984, in Sales, Sales Management and Marketing (CNS, Cardiovascular, Anti-Infectives, Metabolic). He subsequently led the efforts to bring several important new drugs to commercialization including Synagis, while head of Marketing at MedImmune, Inc., from 1995 to 2001, and Cinryze, while head of Commercial Operations (Sales, Sales Management, Marketing, Managed Care, Patient Services, Distribution, FDA Advisory Committee preparation) at Lev Pharmaceuticals, Inc. from 2007 to 2008.
- More recently, from 2017 to 2018, Mr. Duffy was President, Chief Operating Officer and a member of the Board of Directors of AltMed Enterprises, LLC, a medical cannabis company, where he was instrumental in raising capital; executed an overhaul of the company's Arizona operation which led to a significant improvement in productivity; launched the company's first retail dispensary; oversaw the commercial launch of AltMed Florida; restructured the corporate operation and implemented a comprehensive budgeting process.

SCIENTIFIC FOUNDERS / ADVISORS


Mark Poznansky, MD, PhD

Director of the Vaccine and Immunotherapy Center (VIC) and Physician at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Poznansky will serve as both scientific founder and scientific advisory board member to help advise on the early clinical research and implementation of testing in the hospital setting and to help gather additional academic and clinical KOLs to serve on the SAB.

Jeffrey Gelfand, MD

Dr. Jeffrey A. Gelfand is an infectious disease specialist in Boston, Massachusetts. He received his medical degree from Tufts University School of Medicine and has been in practice for more than 20 years. Dr. Gelfand's specializes in infectious disease. He is also a Clinical Professor of Medicine, where he has developed a novel approach for targeting (tumor) antigens whose sequence may not be known or structure even identified.

NEXT STEPS



Manufacturing scale-up for HSP70 and peptides

Animal testing

- HaloVax
- Oncology

IND Filings

IP prosecution

VOLTRON CORPORATE OVERVIEW

VOLTRON is a pre-clinical biotech company focused on bringing our Self-Assembling Vaccines (SAV) to patients with certain cancers or infectious diseases.

Infectious pathogens, such as COVID-19.

- Positive results in generating immunity against COVID-19 in recent animal testing recently reported

Specific cancers, particularly those related to human papilloma virus (HPV)

- We believe that our vaccines could be synergistic with existing therapies and improve patient outcomes by engaging the immune system to identify and attack certain cancers.

Initial proof of concept:

- Lassa Fever and Q Fever, emerging infectious diseases, via MGH research
- This was done, in part, with the support of the Department of Defense (DoD). These same principles are being applied to developing a vaccine against the pandemic coronavirus, known as COVID-19

Oncology development underway, with animal testing to follow

Manufacturing scale-up in process; GMP material for first-in-man studies to be ready in 1Q21

Strong leadership team in place

Strong intellectual property surrounding composition of matter. Incorporating HSP70 more broadly activates the immune system in contrast to prior vaccine efforts which used classic adjuvants like alum, etc. The vaccine is 90% HSP70 and Avidin. Biotinilated Neoantigens are then incorporated to customize the vaccine.



CONTACT

Patrick Gallagher, CEO

973-216-6014

pgallagher@luciuspartnersllc.com

Matthew Duffy, President

646-335-5923

mduffy@luciuspartnersllc.com

James Ahern, Director

917-565-0279

jahern@luciuspartnersllc.com